
## What is claimed is:

1. A compound or a pharmaceutically acceptable salt, isomer, polymorph or solvate thereof, a chemical structural formula of the compound is shown in Formula I:





;

I

wherein the isomer is selected from a group consisting of an enantiomer, a diastereoisomer, a cis-trans isomer and a stereoisomer.

2. A preparation method for the compound according to claim 1, comprising: hydrolyzing a compound of Formula 1-12 to prepare and obtain the compound of Formula I, with the following reaction equation:




.

3. The preparation method according to claim 2, wherein the hydrolyzing is carried out in the presence of a base.

4. Use of the compound or the pharmaceutically acceptable salt, isomer, polymorph, or solvate thereof according to claim 1 in preparing a drug; wherein the isomer is selected from a group

consisting of an enantiomer, a diastereoisomer, a cis-trans isomer, and a stereoisomer.

5. The use according to claim 4, wherein the drug is a gonadotropin-releasing hormone receptor antagonist.

6. Use of the compound or the pharmaceutically acceptable salt, isomer, polymorph, or solvate thereof according to claim 1 in the preparation of a drug for the treatment of a gonadal hormone-related disease;
wherein the isomer is selected from a group consisting of an enantiomer, a diastereoisomer, a cis-trans isomer, and a stereoisomer;
wherein the gonadal hormone-related disease is selected from a group consisting of endometriosis, amenorrhea, menstrual irregularity, hysteromyoma, metrofibroma, polycystic ovarian disease, uterine leiomyoma, lupus erythematosus, hirsutism, precocious puberty, dwarfism, acne, alopecia, gonadotropin-dependent tumor, gonadotropin-producing pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception and infertility, and Alzheimer’s disease.

7. The use according to claim 6, wherein the gonadotropin-dependent tumor is selected from a group consisting of prostate cancer, uterine cancer, breast cancer, ovarian cancer, and pituitary gonadotropic adenomas.

8. A drug composition, comprising the compound or the pharmaceutically acceptable salt, isomer, polymorph or solvate thereof according to claim 1; wherein the isomer is selected from a group consisting of an enantiomer, a diastereoisomer, a cis-trans isomer, and a stereoisomer.